FGF23 Reduction : Efficacy of a New Phosphate Binder in CHronic Kidney Disease
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate in Chronic Kidney Disease (CKD) patients not on
dialysis and who have an Fibroblast growth factor 23 (FGF23) serum levels elevated, the
effect of non calcic phosphate binder: sevelamer carbonate. This treatment could lead to a
diminution of FGF23 serum levels due to the diminution of intestinal absorption of dietary
phosphate. In addition, the investigators will describe the impact of the FGF23 level
monitoring on the main phosphocalcium metabolism markers as phosphatemia, intact parathyroid
hormone (iPTH), serum calcitriol and phosphaturia.